Barr spots a market
Barr Laboratories has launched its AB-rated generic equivalent version of Roche Pharmaceutical's Accutane Capsules, 10 mg, 20 mg and 40 mg, under the trademark name Claravis (Isotretinoin Capsules, USP). The FDA approved the company's application to manufacture and market Claravis in April 2003.
Barr Laboratories has launched its AB-rated generic equivalent version of Roche Pharmaceutical's Accutane Capsules, 10 mg, 20 mg and 40 mg, under the trademark name Claravis (Isotretinoin Capsules, USP). The FDA approved the company's application to manufacture and market Claravis in April 2003.
Barr will promote Claravis to dermatologists using its sales force that currently markets Trexall (Methotrexate Tablets, USP).
Claravis is indicated for the treatment of severe recalcitrant nodular acne. Because of significant adverse effects associated with its use, Claravis should be reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics. In addition, for female patients of childbearing potential, Claravis is indicated only for those females who are not pregnant and will not become pregnant.
Claravis will compete in the Accutane marketplace that had total annual sales of approximately $536m for the most recent twelve months ended March 2003.